Endoscopic mucosal resection with precutting vs. anchoring technique using snare tip for 10-25 mm nonpedunculated colorectal polyps: a randomized controlled trial.

Eur J Gastroenterol HepatolApr 17, 2026 (epub)
Clinical ResearchGastroenterology

Jong Yoon Lee, Hee Yoon Noh, Yang Hyun Baek et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared precutting EMR (P-EMR) and anchoring EMR (A-EMR) techniques for resecting nonpedunculated colorectal polyps sized 10-25 mm. Both techniques achieved high R0 resection rates (93.7% for P-EMR vs. 88.9% for A-EMR), but A-EMR had significantly shorter injection-to-snaring and total procedure times.

Key findings

  • R0 resection rates were 93.7% for P-EMR and 88.9% for A-EMR, with no significant difference (P = 0.344).
  • A-EMR had a significantly shorter injection-to-snaring time of 181.8 ± 81.9 seconds compared to 320.9 ± 143.5 seconds for P-EMR (P < 0.001).
  • Total procedure time was significantly shorter for A-EMR at 259.7 ± 139.7 seconds versus 479.8 ± 249.0 seconds for P-EMR (P < 0.001).
  • Adverse events were comparable between both techniques.

Why it matters

Understanding the efficiency and effectiveness of different EMR techniques is crucial for optimizing colorectal polyp management. This study highlights that while both methods are effective, A-EMR may offer time-saving benefits in clinical practice.

Source

Published in Eur J Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.